Decipher Labs Limited announced that it is in the business of pharmaceutical manufacturing, distribution, sales, and business support services along with diversified intrests in the Information Technology industry through its subsidiaries. The company, in its endeavor for growth, constantly looks at various proposals for expansion of the business of the company while scouting for new avenues in the Pharma and Information Technology Sectors and various other business expansion strategies. The Company is considering the business expansion of its portfolio to cater to retail sales of medicines by opening and operating pharmacies and online marketing and sales globally. With the foray into the retail segment, the company envisages to achieve robust growth through high volume sales. The latest proposed expansion gels well with the business outlook of the company as it envisages to capitalize on its brand values and nationwide presence thus enabling a nationwide franchise by providing a commercially viable proposition. The Board proposes to create a separate subsidiary company to market various formulations and other allied products including neutraceuticals, herbal and ayurvedic medications and other allied products. The company proposes to have a soft launch of its services in Hyderabad and expand to the states of South India initially and further expand across India. The company expects to cater to a vast majority of drugs for recurring and chronic ailments apart from over-the-counter products for health, wellness, and personal care and lifestyle medications including neutraceuticals, herbal and ayurvedic medications and other allied products. The Board with a view of making the company's global presence in the field of Pharma, is also on the lookout for strategic alliances to further expand its presence domestically and internationally. The company expects to initiate the process of obtaining requisite approvals and subject to statutory approvals, start commercial sales and expand its revenue base as early as the end this year.